HCW9218 for Advanced Pancreatic Cancer

Status Active, not recruiting

Clinical Trial Summary

This is a Phase 1b/2, open-label, multi-center, competitive enrollment and dose-escalation study of HCW9218 in patients with advanced/metastatic pancreatic cancer.

Clinical Trial Description

The study involves a Phase 1b dose escalation portion with up to 30 patients to determine the MTD using a 3+3 dose escalation design and to designate a dose level for the Phase 2 expansion phase (RP2D). The Phase 2 portion of the study will consist of an expansion cohort of up to 39 patients receiving HCW9218 monotherapy at the RP2D level. An additional independent Phase 2 cohort of patients receiving HCW9218 at the RP2D level in sequence with gemcitabine and nab-paclitaxel will also be considered. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05304936
Study type	Interventional
Source	HCW Biologics
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	October 17, 2022
Completion date	February 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01454180` - Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets	Phase 2
Recruiting	`NCT05620732` - Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T	N/A
Recruiting	`NCT05053971` - Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas	Phase 1/Phase 2
Recruiting	`NCT05733000` - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	Phase 2
Recruiting	`NCT05143151` - CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer	Phase 1/Phase 2
Withdrawn	`NCT05238831` - SMMART Adaptive Clinical Treatment (ACT) Trial	Early Phase 1
Recruiting	`NCT05759923` - First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours	Phase 1
Recruiting	`NCT05526443` - Austrian Registry for Evaluation of Treatment Patterns and Outcome in Patients With Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
Not yet recruiting	`NCT05257122` - A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer	Phase 2
Completed	`NCT03033225` - Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study	Phase 2
Recruiting	`NCT05969860` - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer	Phase 2
Recruiting	`NCT04550494` - Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	Phase 2